Author(s):
Leruez-Ville, Marianne ; Chatzakis, Christos ; Lilleri, Daniele ; Blazquez-Gamero, Daniel ; Alarcon, Ana ; Bourgon, Nicolas ; Foulon, Ina ; Fourgeaud, Jacques ; Gonce, Anna ; Jones, Christine E. ; Klapper, Paul ; Krom, André ; Lazzarotto, Tiziana ; Lyall, Hermione ; Paixão, Paulo ; Papaevangelou, Vassiliki ; Puchhammer, Elisabeth ; Sourvinos, George ; Vallely, Pamela ; Ville, Yves ; Vossen, Ann
Date: 2024
Persistent ID: http://hdl.handle.net/10362/166251
Origin: Repositório Institucional da UNL
Subject(s): Congenital cytomegalovirus infection; Guidelines; Neonatal; Postnatal; Prenatal; Internal Medicine; Oncology; Health Policy; SDG 3 - Good Health and Well-being
Description
Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence and a 17–20% chance of serious long-term effects in children. Since the last guidelines, our understanding, particularly regarding primary maternal infections, has improved. A cCMV guidelines group was convened under the patronage of the European Society of Clinical Virology in April 2023 to refine these insights. The quality and validity of selected studies were assessed for potential biases and the GRADE framework was employed to evaluate quality of evidence across key domains. The resulting recommendations address managing cCMV, spanning prevention to postnatal care. Emphasizing early and accurate maternal diagnosis through serological tests enhances risk management and prevention strategies, including using valaciclovir to prevent vertical transmission. The guidelines also strive to refine personalized postnatal care based on risk assessments, ensuring targeted interventions for affected families.
